Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, a
Autor:
Kenneth L. McClain, Eric D. Jacobsen, Mark L. Heaney, James A. Whitlock, Carlos Rodriguez-Galindo, Cornfeld Mark J, Carl E. Allen, Robert B. Noble, Sarah R. Vaiselbuh, Shannon R. Morris, Deborah A. Smith, Amy A. Murnane, Robert J. Arceci, Robert Vassallo, Beth Ann Reedy, Alison Portnoy, Ira J. Dunkel
Publikováno v:
Pediatric bloodcancer. 64(5)
Background Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including multisystem involvement and systemic inflammatory symptoms. The AKT pathway is relevant to survival and proliferation
Autor:
Shannon R. Morris, Azeem Saleem, Ademi Santiago-Walker, Sam J. Madison, Nona Rama, Cristian Salinas, Roberto Dina, Sarah P. Blagden, Hatice Gungor, Hani Gabra, Mona El-Bahrawy, Edward Curry, Roshan Agarwal, Michele Chen, Deborah A. Smith, Sabin Carme, Euan A. Stronach, Emily Pickford, Elizabeth C. Krachey, Syed Babar
AKT (a serine/threonine-specific protein kinase) regulates many cellular processes contributing to cytotoxic drug resistance. This study’s primary objective examined the relationship between GSK2141795, an oral, pan-AKT inhibitor, and 18F-FDG PET m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18310a199ad5d7fa6cd893fc9ec3c92b
http://hdl.handle.net/10044/1/44102
http://hdl.handle.net/10044/1/44102
Autor:
Thomas A. Lampkin, Emily K. Bergsland, Deborah A. Smith, Neeraj Agarwal, Razelle Kurzrock, Ruud van der Noll, Petronella O. Witteveen, Michael Durante, Joseph F. Kleha, Laurel M. Adams, Shannon R. Morris, Rahul Aggarwal, David S. Hong, Pamela N. Munster, E. Claire Dees, Jennifer M. Specht, Theresa L. Werner, Jan H.M. Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(8)
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors. Materials and Method
Autor:
S. Gail Eckhardt, Gerald S. Falchook, Razelle Kurzrock, Carlos Becerra, Howard A. Burris, Keith T. Flaherty, Ngocdiep T. Le, Douglas J. DeMarini, Donna S. Cox, Vijay Gopal Reddy Peddareddigari, Sujatha Nallapareddy, Wells A. Messersmith, Leslie A. Fecher, Michael S. Gordon, Shannon R. Morris, Jeffrey R. Infante, Johanna C. Bendell, Yanmei Xu, Lowell L. Hart
Publikováno v:
The Lancet. Oncology. 13(8)
Summary Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose
Autor:
Uday B. Dandamudi, Raymond J. Hohl, Brendan M. Johnson, Lionel D. Lewis, R. Timothy Webb, Laurel M. Adams, Sharon C. Murray, Shannon R. Morris, John W. Bauman, Elaina M. Gartner
Publikováno v:
Cancer chemotherapy and pharmacology. 67(4)
The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel.Fourteen cancer patients were enrolled in
Autor:
Shannon R, Morris, Lisa A, Carey
Publikováno v:
Oncology (Williston Park, N.Y.). 20(14)
Up to 25% of patients diagnosed with breast cancer have tumors that overexpress HER2. HER2-positive breast cancer is highly proliferative, difficult to treat, and confers a poor prognosis. The advent of the anti-HER2 monoclonal antibody trastuzumab (